Journal
EBIOMEDICINE
Volume 22, Issue -, Pages 133-142Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.ebiom.2017.07.010
Keywords
C-reactive protein; Complement response; Immunotherapy; Severe influenza infection
Funding
- Young Scholar Scientific Researcher Foundation of China CDC [2015A 101]
- National Natural Science Foundation of China [81373107]
- National Mega-Projects for Infectious Diseases [2017ZX10304402-001-019, 2014ZX10004002]
Ask authors/readers for more resources
Severe influenza diseases with highmortality have been frequently reported, especially in those patients infected with avian influenza A (H5N1, H7N9 or H10N8) or during a pandemic. Respiratory distress, which is attributed to alveolar damage associated with immunopathological lesions, is the most common cause of death. There is a wealth of information on pathogenesis or treatment options. In this study, we showed that high levels of C-reactive protein (CRP) were induced and correlated with complement activation in patients infected with severe influenza A (H5N1, H7N9 or H10N8), and higher levels were induced in fatal patients than in survivors. CRP treatment enhanced the phagocytosis of monocytes THP-1 to H5N1 virus aswell as the expression of proinflammatory cytokines or apoptosis-associated genes in THP-1 cells or pneumocytes A-549 respectively. CRP may link to proinflammatory mediators contributing to activation of complement and boosting inflammatory response in severe influenza infections. Compound 1,6-bis(phosphocholine)-hexane improved the severity and mortality of mice infected with lethal influenza virus significantly. These observations showed that CRP is involved in deterioration of severe influenza diseases, and indicated a substantial candidatemolecule for immunotherapy of severe influenza diseases. (C) 2017 The Authors. Published by Elsevier B.V.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available